Definition of Core elements
C矿元素的定义

Core elements are those which are essential for the clinical management, staging or prognosis of the cancer. These elements will either have evidentiary support at Level III-2 or above (based on prognostic factors in the National Health and Medical Research Council (NHMRC) levels of evidence¹). In rare circumstances, where level III-2 evidence is not available an element may be made a core element where there is unanimous agreement in the expert committee. An appropriate staging system, e.g., Pathological TNM staging, would normally be included as a core element. The summation of all core elements is considered to be the minimum reporting standard for a specific cancer.
C矿石元素是那些对癌症的临床管理、分期或预后至关重要的元素。这些要素将在 III-2 级或更高级别获得证据支持（基于国家健康和医学研究委员会 （NHMRC） 证据级别 1 中的预后因素）。在极少数情况下，在无法获得III-2级证据的情况下，如果专家委员会一致同意，则可以将某个要素作为核心要素。适当的分期系统，例如病理性 TNM 分期，通常会作为核心要素包括在内。 所有 c矿石元素的总和被认为是特定癌症的最低报告标准。

Reference
参考 

1 Merlin T, Weston A and Tooher R (2009). Extending an evidence hierarchy to include topics other than treatment: revising the Australian 'levels of evidence'. BMC Med Res Methodol 9:34.
1 Merlin T、Weston A 和 Tooher R （2009）。扩大证据层次结构，包括治疗以外的主题：修订澳大利亚的“证据水平”。BMC Med Res Methodol 9：34。

Definition of Non-core elements
N个核心元素的定义

Non-core elements are those which are unanimously agreed should be included in the dataset but are not supported by level III-2 evidence. These elements may be clinically important and recommended as good practice but are not yet validated or regularly used in patient management.
N个核心元素是那些一致同意应包含在数据集中但没有得到 III-2 级证据支持的元素。这些要素可能在临床上很重要，并被推荐为良好实践，但尚未得到验证或在患者管理中经常使用。

Key information other than that which is essential for clinical management, staging or prognosis of the cancer such as macroscopic observations and interpretation, which are fundamental to the histological diagnosis and conclusion e.g., macroscopic tumour details, may be included as either core or non-core elements by consensus of the Dataset Authoring Committee.
除了对癌症的临床管理、分期或预后至关重要的信息外，其他关键信息（例如宏观观察和解释）对组织学诊断和结论至关重要的信息，例如宏观肿瘤细节，经 数据集编写委员会协商一致，可作为核心或非核心元素包括在内。

Scope of this dataset
此数据集的范围

The dataset has been developed for biopsy and resection specimens of neoplasms of the heart, pericardium, and great vessels. It includes both benign and malignant primary tumours of the heart, pericardium, and great vessels.
该数据集是为心脏、心包和大血管肿瘤的活检和切除标本而开发的。它包括心脏、心包和大血管的良性和恶性原发性肿瘤。

Mesothelioma and haematolymphoid neoplasms (such as primary cardiac lymphoma) are not included in this dataset. For pericardial mesotheliomas refer to the International Collaboration on Cancer Reporting (ICCR) Mesothelioma in the pleura and peritoneum dataset.¹ Haematolymphoid tumours will be covered in a future ICCR dataset. Metastatic lesions should not be recorded using this dataset.
间皮瘤和血淋巴样肿瘤（如原发性 心脏淋巴瘤）不包括在此数据集中。对于心包间皮瘤，请参阅国际癌症报告协作组织 （ICCR） 胸膜和腹膜数据集中的间皮瘤。¹ 血淋巴样肿瘤将包含在未来的 ICCR 数据集中。不应使用此数据集记录转移性病变。

There is currently no agreed-upon staging system (such as TNM) for cardiac tumours, due to an insufficiency of evidence.
由于证据不足，目前没有商定的心脏肿瘤分期系统（如TNM）。

The second edition includes changes to align the dataset with the World Health Organization (WHO) Classification of Thoracic Tumours, 5^th edition, 2021.²
第二版包括更改，以使数据集与世界卫生组织 （WHO） 胸部肿瘤分类，第 5 版，2021 年。^{阿拉伯数字}

References
引用

1 International Collaboration on Cancer Reporting (2021). Mesothelioma in the Pleura and Peritoneum Histopathology Reporting Guide. Available from: http://www.iccr-cancer.org/datasets/published-datasets/thorax/mesothelioma (Accessed 10th November 2021).
1 癌症报告国际合作组织（2021 年）。 胸膜和腹膜间皮瘤组织病理学报告指南。 可从：http://www.iccr-cancer.org/datasets/published-datasets/thorax/mesothelioma（2021 年 11 月 10 日访问）。

2 WHO Classification of Tumours Editorial Board (2021). Thoracic Tumours, 5th Edition, Volume 5. IARC Press, Lyon.
2 世界卫生组织肿瘤分类编辑委员会（2021 年）。 胸部肿瘤，第 5 版，第 5 卷。IARC出版社，里昂。

Core/
C矿/

Non-core
非核心

Element name
元素名称

Values
值

Commentary
评论

Implementation notes
实施说明

Core
核心

OPERATIVE PROCEDURE
手术程序

Not specified
未指定

Resection
切除术

Endovascular biopsy
血管内活检

Image guided percutaneous biopsy
影像引导下经皮活检

Explantation
移植

Other, specify
其他，指定

As there may be more than one approach or technique to removing or sampling a tumour at a given location within the heart, specifying the nature of the operative procedure to the extent possible is important and is therefore a core element.^1,2
由于可能有多种方法或技术可以在心脏内的给定位置切除或取样肿瘤，因此尽可能指定手术程序的性质很重要，因此是一个核心要素。^1,2

References
引用

1 Burke AP, Tavora F, Maleszewski J and Frazier A (2015). Tumors of the Heart and Great Vessels. AFIP Atlas of Tumor Pathology, Series 4. ARP Press, Washington DC.
1 Burke AP、Tavora F、Maleszewski J 和 Frazier A （2015）。 心脏和大血管的肿瘤。AFIP 肿瘤病理学图谱，系列 4。ARP出版社，华盛顿特区。

2 Bakaeen FG, Jaroszewski DE, Rice DC, Walsh GL, Vaporciyan AA, Swisher SS, Benjamin R, Blackmon S and Reardon MJ (2009). Outcomes after surgical resection of cardiac sarcoma in the multimodality treatment era. J Thorac Cardiovasc Surg 137(6):1454-1460.
2 Bakaeen FG、Jaroszewski DE、Rice DC、Walsh GL、Vaporciyan AA、Swisher SS、Benjamin R、Blackmon S 和 Reardon MJ（2009 年）。多模式治疗时代心脏肉瘤手术切除后的结果。胸心血管外科杂志 137（6）：1454-1460。

Core
核心

TUMOUR SITE
肿瘤部位

Not specified
未指定

Atrium
心房

Left
左

Right
右

Laterallity not specified
未指定偏侧性

Ventricle
心室

Left
左

Right
右

Laterallity not specified
未指定偏侧性

Endocardial
心内膜

Myocardial
心肌

Epicardial
心外膜

Septum
隔膜

Free wall
免费墙

Parietal pericardium
壁心包

Valve, specify
阀门，指定

Great vessel, specify
伟大的船只，指定

Other, specify
其他，指定

The tumour site within the heart has implications in terms of obstruction of blood flow, valvular dysfunction, and potential embolisation and haematogenous spread to downstream vascular beds.^1,2 All sites including the chamber and substructures that are involved by tumour should be listed.³ An accurate listing of sites of tumour involvement may require radiological and intra-operative correlation.
心脏内的肿瘤部位在血流阻塞、瓣膜功能障碍以及可能的栓塞和血源性扩散到下游血管床方面具有影响。^1,2 应列出肿瘤涉及的所有部位，包括腔室和子结构。³ 准确列出肿瘤受累部位可能需要放射学和术内相关性。

References
引用

1 Burke AP, Tavora F, Maleszewski J and Frazier A (2015). Tumors of the Heart and Great Vessels. AFIP Atlas of Tumor Pathology, Series 4. ARP Press, Washington DC.
1 Burke AP、Tavora F、Maleszewski J 和 Frazier A （2015）。 心脏和大血管的肿瘤。AFIP 肿瘤病理学图谱，系列 4。ARP出版社，华盛顿特区。

2 Siontis BL, Leja M and Chugh R (2020). Current clinical management of primary cardiac sarcoma. Expert Rev Anticancer Ther 20(1):45-51.
2 Siontis BL、Leja M 和 Chugh R （2020）。原发性心脏肉瘤的当前临床管理。专家修订抗癌 20（1）：45-51。

3 Scicchitano P, Sergi MC, Cameli M, Miglioranza MH, Ciccone MM, Gentile M, Porta C and Tucci M (2021). Primary Soft Tissue Sarcoma of the Heart: An Emerging Chapter in Cardio-Oncology. Biomedicines 9(7):774 doi: 710.3390/biomedicines9070774.

Core
C矿

MAXIMUM DIMENSION OF PRIMARY TUMOUR
原发性肿瘤的最大尺寸

____ mm
____毫米

Cannot be assessed
无法评估

This element applies only to resection and explant specimens in which the entire tumour can be measured. Reporting the size in biopsy and other incomplete tumour samples may be misleading clinically.
该元素仅适用于可以测量整个肿瘤的切除和外植体标本。报告活检和其他不完整肿瘤样本的大小可能在临床上具有误导性。

Applicable for resection and explant specimens only.
仅适用于切除和外植体标本。

Core
C矿

TUMOUR FOCALITY
肿瘤病灶性

Indeterminate
定

Unifocal
单焦点

Multifocal, specify number of tumours in specimen and
多焦点，指定标本中的肿瘤数量和

their locations
他们的位置

Multiple tumours may be present at the same site or at different sites. A single tumour may invade multiple structures and thereby also be present in multiple cardiac locations. The tumour focality element clarifies this issue and is therefore a core element.
多个肿瘤可能存在于同一部位或不同部位。单个肿瘤可能侵入多个结构，因此也存在于多个心脏部位。肿瘤焦点性要素澄清了这个问题，因此是一个核心要素。

Non-core
非核心

BLOCK IDENTIFICATION KEY
块标识键

List overleaf or separately with an indication of the nature and origin of all tissue blocks
在叶子上或单独列出，并注明所有组织块的性质和来源

The origin/designation of all tissue blocks should be recorded. This information should be documented in the final pathology report and is particularly important should the need for internal or external review arise. The reviewer needs to be clear about the origin of each block in order to provide an informed specialist opinion. If this information is not included in the final pathology report, it should be available on the laboratory computer system and relayed to the reviewing pathologist. 
应记录所有组织块的来源/名称。这些信息应记录在最终的病理报告中，如果需要进行内部或外部审查，这些信息尤为重要。审查者需要清楚每个区块的来源，以便提供明智的专家意见。如果这些信息未包含在最终病理报告中，则应在实验室计算机系统上提供该信息，并将其转发给审查病理学家。

Recording the origin/designation of tissue blocks also facilitates retrieval of blocks for further immunohistochemical or molecular analysis, research studies, or clinical trials.
记录组织块的来源/名称还有助于检索块，以便进行进一步的免疫组织化学或分子分析、研究或临床试验。

Core
核心

HISTOLOGICAL TUMOUR TYPE
组织学肿瘤类型

Heart
心

BENIGN
良性

Papillary fibroelastoma
状弹性纤维瘤

Cardiac myxoma
心肌粘液瘤

Cardiac fibroma
心脏纤维瘤

Cardiac rhabdomyoma
心脏横纹肌瘤

Adult cellular rhabdomyoma
成人细胞横纹肌瘤

Cardiac lipoma
心脏脂肪瘤

Lipomatous hypertrophy of atrial septum
房间隔脂肪瘤性肥大

Lipomatous hamartoma of atrioventricular valve
房室瓣脂肪瘤性错构瘤

Hamartoma of mature cardiac myocytes
成熟心肌细胞错构瘤

Mesenchymal cardiac hamartoma
间充质心脏错构瘤

Cardiac haemangioma
心脏血管瘤

Capillary
毛细管

Arteriovenous
动静脉的

Cavernous
海绵 状

Venous
静脉的

Conduction system hamartoma
传导系统错构瘤

Cystic tumour of atrioventricular node
房室结囊性肿瘤

MALIGNANT
恶性

Cardiac angiosarcoma
心脏血管肉瘤

Cardiac leiomyosarcoma
心脏平滑肌肉瘤

Cardiac undifferentiated pleomorphic sarcoma
心脏未分化多形性肉瘤

Other sarcoma, specify
其他肉瘤，请具体说明

TUMOURS OF UNCERTAIN BEHAVIOUR
行为不明的肿瘤

Inflammatory myofibroblastic tumour
炎性肌成纤维细胞瘤

Paraganglioma
副神经节瘤

Solitary fibrous tumour
孤立性纤维瘤

Mixed germ cell tumour
混合生殖细胞瘤

Angiosarcoma
血管肉瘤

Other, specify
其他，指定

Great vessels
伟大的船只

Angiosarcoma
血管肉瘤

Pulmonary artery intimal sarcoma
肺动脉内膜肉瘤

Other, specify
其他，指定

Neoplastic entities occurring in the heart, pericardium, and great vessels should be classified according to the most recent edition of the WHO Classification of Thoracic Tumours, 5^th edition, 2021 (Table 1).¹ The neoplastic nature of some space-occupying lesions (lipomatous hypertrophy of the atrial septum, vascular malformations, hamartoma of mature cardiac myocytes, conduction system hamartoma, etc.) is not entirely clear.^2,3 Whether or not this dataset should be used on these lesions is left to the discretion of the pathologist.
发生在心脏、心包和大血管中的肿瘤实体应根据最新版本的 WHO 胸部肿瘤分类 2021 ^年第 5 版（表 1）进行分类。 ¹ 一些占位性病变（房间隔脂肪瘤肥大、血管畸形、成熟心肌细胞错构瘤、传导系统错构瘤等）的肿瘤性质尚不完全清楚。^2,3 该数据集是否应用于这些病变由病理学家自行决定。

Table 1 (See end of the document for tables)
表1（见文件末尾f或表s）

References
引用

1 WHO Classification of Tumours Editorial Board (2021). Thoracic Tumours, 5th Edition, Volume 5. IARC Press, Lyon.
1 世界卫生组织肿瘤分类编辑委员会（2021 年）。 胸部肿瘤，第 5 版，第 5 卷。IARC出版社，里昂。

2 Burke AP, Tavora F, Maleszewski J and Frazier A (2015). Tumors of the Heart and Great Vessels. AFIP Atlas of Tumor Pathology, Series 4. ARP Press, Washington DC.
2 Burke AP、Tavora F、Maleszewski J 和 Frazier A （2015）。 心脏和大血管的肿瘤。AFIP 肿瘤病理学图谱，系列 4。ARP出版社，华盛顿特区。

3 Chen TW, Loong HH, Srikanthan A, Zer A, Barua R, Butany J, Cusimano RJ, Liang YC, Chang CH, Iakobishvili Z, Razak ARA and Lewin J (2019). Primary cardiac sarcomas: A multi-national retrospective review. Cancer Med 8(1):104-110.
3 Chen TW、Loong HH、Srikanthan A、Zer A、Barua R、Butany J、Cusimano RJ、Liang YC、Chang CH、Iakobishvili Z、Razak ARA 和 Lewin J （2019）。原发性心脏肉瘤：一项多国回顾性评价。癌症医学 8（1）：104-110。

4 Fritz A, Percy C, Jack A, Shanmurgaratnam K, Lobin L, Parkin DM and Whelan S (eds) (2020). International Classification of Diseases for Oncology. Third edition, Second revision ICD-O-3.2. Available from: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577 (Accessed 16th June 2021).
4 Fritz A、Percy C、Jack A、Shanmurgaratnam K、Lobin L、Parkin DM 和 Whelan S（编辑）（2020 年）。 国际肿瘤疾病分类。第三版，第二版ICD-O-3.2。可从：http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577（2021 年 6 月 16 日访问）。

Value list based on the
基于

WHO Classification of Thoracic Tumours (2021)
WHO 胸部肿瘤分类 （2021）.

Note that permission to publish the WHO Classification of Tumours may be needed in your implementation. It is advisable to check with the International Agency for Research on Cancer.
请注意，在您的实施过程中可能需要获得发布 WHO 肿瘤分类的许可。建议向国际癌症研究机构查询。

Core and Non-core
核心和非核心

HISTOLOGICAL TUMOUR GRADE
组织学肿瘤分级

Cannot be graded
无法分级

Grade 1
1级

Grade 2
2级

Grade 3
三年级

Ungraded sarcoma
未分级肉瘤

Necrosis
坏死

Cannot be assessed
无法评估

Not identified
未识别

Present
目前

Extent of necrosis ____ %
坏死程度 ____ %

Mitotic count ____ /mm²
有丝分裂计数 ____ /mm²

(most proliferative area)
（最增殖的区域）

This element only applies to sarcomas of the heart, pericardium, and great vessels. This element captures information shown to be prognostically important in sarcomas at other body sites.¹ Evidence that these have the same importance in sarcomas of the heart, pericardium, and great vessels is lacking.^2,3
该元素仅适用于心脏、心包和大血管的肉瘤。该元素捕获在其他身体部位的肉瘤中显示对预后具有重要意义的信息。¹ 缺乏证据表明这些物质在心脏、心包和大血管肉瘤中具有同样的重要性。^2,3

There is no formal grading system for cardiac tumours. However, the French Federation of Cancer Centers Sarcoma Group (FNCLCC) system for the grading of sarcomas⁴ can be used as a guide. The FNCLCC system includes an assessment of mitotic activity, necrosis, nuclear grade and cellularity (refer to Table 2).
心肌肿瘤没有正式的分级系统。然而，法国癌症中心联合会肉瘤组 （FNCLCC） 的肉瘤 ⁴ 分级系统可作为指导。FNCLCC系统包括对有丝分裂活性、坏死、核级和细胞性的评估（参见表2）。

Necrosis
坏死

The extent of necrosis is estimated as a percentage of total tumour.
坏死的程度估计为占肿瘤总量的百分比。

Mitotic count
有丝分裂计数

Mitotic count is a non-core element. If recorded it should be expressed as ’#/mm²’ due to the fact that differing field diameters of high power (x40) objectives dramatically vary the size of a single high power field (HPF).
有丝分裂计数是一个非核心元素。如果记录，则应表示为“#/mm²”，因为高功率（x40）物镜的不同视场直径会极大地改变单个高功率视场（HPF）的大小。

Table 2 (See end of the document for tables)
表 2（表格见文档末尾）

The scores for these variables are added to calculate the following values:
将这些变量的分数相加以计算以下值：

Grade 1 - Total score of 2 or 3
1 年级 - 总分 2 或 3 分

Grade 2 - Total score of 4 or 5
2 年级 - 总分 4 或 5 分

Grade 3 - Total score of 6 or higher.
3 级 - 总分 6 分或更高。

References
引用

1 International Collaboration on Cancer Reporting (2021). Soft Tissue Sarcoma Histopathology Reporting Guide - Resection Specimens, 1st edition. Available from: http://www.iccr-cancer.org/datasets/published-datasets/soft-tissue-bone/soft-tissue-sarcoma-resection-specimens (Accessed 10th November 2021).
1 癌症报告国际合作组织（2021 年）。 软组织肉瘤组织病理学报告指南 - 切除标本，第 1 版。 可从：http://www.iccr-cancer.org/datasets/published-datasets/soft-tissue-bone/soft-tissue-sarcoma-resection-specimens（2021 年 11 月 10 日访问）。

2 Trojani M, Contesso G, Coindre JM, Rouesse J, Bui NB, de Mascarel A, Goussot JF, David M, Bonichon F and Lagarde C (1984). Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 33:37-42.
2 Trojani M、Contesso G、Coindre JM、Rouesse J、Bui NB、de Mascarel A、Goussot JF、David M、Bonichon F 和 Lagarde C（1984 年）。成人软组织肉瘤;病理预后变量的研究和组织病理学分级系统的定义。国际癌症杂志 33：37-42。

3 Burke AP, Tavora F, Maleszewski J and Frazier A (2015). Tumors of the Heart and Great Vessels. AFIP Atlas of Tumor Pathology, Series 4. ARP Press, Washington DC.
3 Burke AP、Tavora F、Maleszewski J 和 Frazier A （2015）。 心脏和大血管的肿瘤。AFIP 肿瘤病理学图谱，系列 4。ARP出版社，华盛顿特区。

4 Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, Vilain MO, Mandard AM, Le D V, Leroux A, Jacquemier J, Duplay H, Sastre-Garau X and Costa J (1997). Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 15:350-362.
4 Guillou L、Coindre JM、Bonichon F、Nguyen BB、Terrier P、Collin F、Vilain MO、Mandard AM、Le D V、Leroux A、Jacquemier J、Duplay H、Sastre-Garau X 和 Costa J （1997）。美国国家癌症研究所和法国癌症中心联合会肉瘤组分级系统在 410 名成年软组织肉瘤患者中的比较研究。临床肿瘤杂志 15：350-362。

5 Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM and Meyer LR (eds) (2017). AJCC Cancer Staging Manual. 8th ed., Springer, New York.
5 Amin MB、Edge SB、Greene FL、Byrd DR、Brookland RK、Washington MK、Gershenwald JE、Compton CC、Hess KR、Sullivan DC、Jessup JM、Brierley JD、Gaspar LE、Schilsky RL、Balch CM、Winchester DP、Asare EA、Madera M、Gress DM 和 Meyer LR（编辑）（2017 年）。 AJCC癌症分期手册。 第 8 版。，斯普林格，纽约。

Applicable to sarcomas only
仅适用于肉瘤.

Core
核心

EXTENT OF INVASION
侵入程度

Cannot be assessed
无法评估

Intracardiac invasion
心内浸润

Extracardiac invasion (i.e., into the great vessels or beyond the parietal pericardium), specify structures
心外浸润（即进入大血管或壁室心包以外），具体说明结构

Intraluminal/intracavitary extension, specify
腔内/腔内延伸，指定

For the purposes of this data element, the parietal pericardium represents the anatomic boundary between the heart tissues and adjacent organs. Tumours that extend into the great vessels or beyond the parietal pericardium (such as into the pleura, oesophagus, diaphragm, or chest wall) should be considered ‘extracardiac invasion’. Tumours crossing tissue boundaries in the heart (e.g., one chamber to another, across a valve, or into the pericardium) should be considered ‘intracardiac invasion’.^1,2
就此数据元素而言，壁体心包表示心脏组织和邻近器官之间的解剖边界。延伸到大血管或壁层心包以外（如进入胸膜、食管、膈肌或胸壁）的肿瘤应被视为“心外浸润”。肿瘤穿过心脏的组织边界（例如，从一个腔室到另一个腔室、穿过瓣膜或进入心包）应被视为“心内浸润”。^1,2

For cases with tumour thrombus/embolus or intraluminal/intracavitary tumour extension, this should be indicated as well as the vessel(s) or chambers involved.
对于肿瘤血栓/栓子或腔内/腔内肿瘤扩展的病例，应注明这一点以及受累的血管或腔室。

References
引用

1 WHO Classification of Tumours Editorial Board (2021). Thoracic Tumours, 5th Edition, Volume 5. IARC Press, Lyon.
1 世界卫生组织肿瘤分类编辑委员会（2021 年）。 胸部肿瘤，第 5 版，第 5 卷。IARC出版社，里昂。

2 Burke AP, Tavora F, Maleszewski J and Frazier A (2015). Tumors of the Heart and Great Vessels. AFIP Atlas of Tumor Pathology, Series 4. ARP Press, Washington DC.
2 Burke AP、Tavora F、Maleszewski J 和 Frazier A （2015）。 心脏和大血管的肿瘤。AFIP 肿瘤病理学图谱，系列 4。ARP出版社，华盛顿特区。

Core
核心

MARGIN STATUS
保证金状态

Cannot be assessed
无法评估

Not involved
不涉及

Involved, specify margin(s
涉及，指定边距)

Applicable for resection and explant specimens only.
仅适用于切除和外植体标本。

Non-core
非核心

LYMPHOVASCULAR INVASION
淋巴血管浸润

Indeterminate
定

Not identified
未识别

Present
目前

Method of evaluation
评估方法

Routine staining (H&E)
常规染色 （H&E）

Immunohistochemistry for lymphovascular endothelium, specify
淋巴血管内皮的免疫组化，指定

This element is commonly reported for malignancies; however, since the majority of tumours in the heart and great vessels exist within the vasculature and have immediate access to haematogenous dissemination, this element should only be reported for pericardial tumours, such as germ cell tumours and solitary fibrous tumour, that do not arise within the vascular system.
据报道，该元素通常用于恶性肿瘤;然而，由于心脏和大血管中的大多数肿瘤存在于脉管系统内，并可立即通过血源性播散，因此仅应报告不适用于不会在血管系统内出现的心包肿瘤，例如生殖细胞肿瘤和孤立性纤维瘤。

Applicable to solitary fibrous and germ cell tumours of the
适用于孤立性纤维瘤和生殖细胞瘤

Pericardium
心包.

Non-core
非核心

ANCILLARY STUDIES
辅助研究

Not performed
未执行

Performed
执行

Immunohistochemistry, specify test(s) and result(s)
免疫组化，指定测试和结果

Molecular pathology, specify test(s) and result(s)
分子病理学，指定测试和结果

Cytogenetics, specify test(s) and result(s)
细胞遗传学，指定测试和结果

Other, specify test(s) and result(s)
其他，指定测试和结果

Representative blocks for ancillary studies, specify those blocks best representing tumour and/or normal tissue for further study
辅助研究的代表性块，指定那些最能代表肿瘤和/或正常组织以供进一步研究的块

While ancillary studies are not essential for the diagnosis of entities in this dataset, immunohistochemistry and molecular studies are often useful in classifying many of the tumours listed herein, particularly the differentiated mesenchymal neoplasms and germ cell tumours.¹ If any additional studies are undertaken, they should be recorded.
虽然辅助研究对于该数据集中实体的诊断不是必需的，但免疫组织化学和分子研究通常可用于对本文列出的许多肿瘤进行分类，尤其是分化的间充质肿瘤和生殖细胞肿瘤。¹ 如果进行任何其他研究，应将其记录在案。

Reference
参考

1 Urbini M, Astolfi A, Indio V, Nannini M, Pizzi C, Paolisso P, Tarantino G, Pantaleo MA and Saponara M (2020). Genetic aberrations and molecular biology of cardiac sarcoma. Ther Adv Med Oncol 12:1758835920918492.
1 乌尔比尼 M、阿斯托尔菲 A、印第奥 V、南尼尼 M、皮齐 C、保利索 P、塔伦蒂诺 G、潘塔莱奥 MA 和萨波纳拉 M（2020 年）。心脏肉瘤的遗传畸变和分子生物学。Ther Adv Med Oncol 12：1758835920918492。

Tumour differentiation 
肿瘤分化

Mitotic count
有丝分裂计数

Tumour necrosis
肿瘤坏死

Sarcoma closely resembling normal adult mesenchymal tissue (e.g., low grade leiomyosarcoma) (1 point)
与正常成人间充质组织非常相似的肉瘤（例如，低级别平滑肌肉瘤）（1 分）

0-9 mitoses per 2mm² (1 point)
每 2mm² 0-9 个有丝分裂 2 （1 点）

No necrosis (0 points)
无坏死 （0 分）

Sarcomas for which histologic typing is certain (e.g., myxoid/round cell liposarcoma) (2 points)
组织学分型确定的肉瘤（例如，粘液样/圆形细胞脂肪肉瘤）（2 分）

10-19 mitoses per 2mm² (2 points)
每 2mm 10-19 个有丝分裂 ² （2 分）

< 50% tumour necrosis (1 point)
< 50% 肿瘤坏死 （1 分）

Undifferentiated sarcomas, sarcomas of doubtful type, synovial sarcomas, osteosarcoma (3 points)
未分化肉瘤、可疑型肉瘤、滑膜肉瘤、骨肉瘤 （3 分）

≥20 mitoses per 2mm² (3 points)
≥20 有丝分裂/2mm ² （3 分）

≥50% tumour necrosis (2 points)
≥50% 肿瘤坏死 （2 分）